Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Bioethics and Medical Ethics (1)
- Biomedical and Dental Materials (1)
- Food and Drug Law (1)
- Genetic Processes (1)
- Law (1)
-
- Medical Biotechnology (1)
- Medical Genetics (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medicinal and Pharmaceutical Chemistry (1)
- Pharmaceutical Preparations (1)
- Pharmaceutics and Drug Design (1)
- Pharmacoeconomics and Pharmaceutical Economics (1)
- Pharmacy Administration, Policy and Regulation (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Keyword
-
- Biological Products (1)
- Biosimilar (1)
- CRISPR/Cas9 (1)
- Casgevy (1)
- Clinical Efficacy Studies (1)
-
- Crizanlizumab (1)
- Drug Approval (1)
- European Medicines Agency (1)
- Genetics (1)
- Hb (1)
- Hemoglobin (1)
- Hydroxyurea (1)
- L-glutamine (1)
- Lyfgenia (1)
- Monoclonal Antibodies (1)
- Pharmacogenetics (1)
- Pharmacogenomics (1)
- SCA (1)
- SCD (1)
- Sickle cell anemia (1)
- Sickle cell disease (1)
- Stem cells (1)
- United States Food and Drug Administration (1)
- Voxelotor (1)
Articles 1 - 2 of 2
Full-Text Articles in Biological Factors
Fda Policy Shift On Clinical Efficacy Study Requirements For Monoclonal Antibody Biosimilars, Rileigh Rahrig, Madilyn Paphanchith, Allie Honigford, Daniella Egbujor, Haley Brown, Jenny Magana Figueroa, Connor Dains, Brenna Hissong, Kyle W. Parker
Fda Policy Shift On Clinical Efficacy Study Requirements For Monoclonal Antibody Biosimilars, Rileigh Rahrig, Madilyn Paphanchith, Allie Honigford, Daniella Egbujor, Haley Brown, Jenny Magana Figueroa, Connor Dains, Brenna Hissong, Kyle W. Parker
Pharmacy and Wellness Review
Biologic products are widely used in the treatment of various disease states, including rheumatoid arthritis, inflammatory bowel disease, cancers, and genetic diseases. These products are derived from proteins and genes produced by living organisms and are subsequently used to treat specific disease states. Due to the complexity of biological products, the costs of research and production are high. Currently, the United States approval pathway requires extensive testing for biologics to be designated as biosimilars, meaning there are no clinically meaningful differences in safety or purity of their active components. These required tests can be redundant, as biosimilars are developed using …
The Application And Innovation Of Casgevy On Sickle Cell Disease, Emily Tackett, Le Thien Truc Pham, Hannah Salamie, Arin Wade, Allison Provenzale, Alexander Defranco, Ashley Jacob, Brianna Lu, Joshua Honaker, Amy Stockert
The Application And Innovation Of Casgevy On Sickle Cell Disease, Emily Tackett, Le Thien Truc Pham, Hannah Salamie, Arin Wade, Allison Provenzale, Alexander Defranco, Ashley Jacob, Brianna Lu, Joshua Honaker, Amy Stockert
Pharmacy and Wellness Review
Casgevy, sickle cell anemia, SCA, sickle cell disease, SCD, CRISPR/Cas9, hydroxyurea, hemoglobin, Hb, l-glutamine, voxelotor, Crizanlizumab, Lyfgenia, stem cells, genetics, pharmacogenetics, pharmacogenomics